Citadel Advisors’s Artelo Biosciences ARTL Stock Holding History

Citadel Advisors’s Portfolio ARTL Stock Details ARTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-140	Closed	-$19.9K	–	12444
2025 Q1	$19.9K	Buy	+140	New	+$25.3K	﹤0.01%	13146
2022 Q1	–	Sell	-32	Closed	-$41K	–	13526
2021 Q4	$41K	Buy	32 +21	+191%	+$37.3K	﹤0.01%	13352
2021 Q3	$22K	Sell	11 -20	-65%	-$45.7K	﹤0.01%	13632
2021 Q2	$88K	Sell	31 -43	-58%	-$132K	﹤0.01%	13016
2021 Q1	$295K	Buy	+74	New	+$285K	﹤0.01%	10893

Other funds holding ARTL

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors's ARTL Position: Q2 2025 in Review

Citadel Advisors sold out of Artelo Biosciences (ARTL) in Q2 2025, closing a stake of 140 shares — an estimated $19.9K sold.

Citadel Advisors first reported a position in ARTL in Q1 2021 and held it in 5 quarters. The position peaked at $295K in Q1 2021. 3 funds tracked by Wall St. Rank hold ARTL as of Q2 2025.

Citadel Advisors reported no remaining Artelo Biosciences position as of Q2 2025 after selling out during the quarter.
Citadel Advisors sold 140 Artelo Biosciences shares in Q2 2025, an estimated $19.9K.
Citadel Advisors first reported a position in Artelo Biosciences in Q1 2021 and held it in 5 quarters.
Citadel Advisors's Artelo Biosciences position peaked at $295K in Q1 2021.
3 funds tracked by Wall St. Rank held Artelo Biosciences as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.